SavedAdd your journal

Journals / The Anatolian Journal of Cardiology / 2020 / Cilt: 23 - Sayı: 1

The implications and requirements of transcatheter aortic valve replacement in low-risk patients

E. Murat TUZCU
Ahmad EDRIS
Pages
2–9
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The use of TAVR in low-risk patients hasimportant implications and requires a multifaceted approach that includes a highly functional multidisciplinary heart team for careful patientselection; a need to understand and help mitigate certain key complications, such as stroke, paravalvular regurgitation, and conduction disturbances; careful data collection for continual outcome assessment and improvement; and the necessary expertize and procedural volume tomaintain excellent outcomes and ensure optimal clinical care pathways. (Anatol J Cardiol 2020; 23: 2-9)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Transcatheter aortic valve replacement (TAVR) is a transformative technology that has changed the management of patients with severe, symptomatic aortic stenosis.
📊
Key Findings & Data:Recent studies using newer generation devices have demonstrated the noninferiority of TAVR as compared with surgical aorticvalve replacement in low-risk patients, supporting the increased utilization and expansion of TAVR.
💡
Conclusion & Impact:The use of TAVR in low-risk patients hasimportant implications and requires a multifaceted approach that includes a highly functional multidisciplinary heart team for careful patientselection; a need to understand and help mitigate certain key complications, such as stroke, paravalvular regurgitation, and conduction disturbances; careful data collection for continual outcome assessment and improvement; and the necessary expertize and procedural volume tomaintain excellent outcomes and ensure optimal clinical care pathways. (Anatol J Cardiol 2020; 23: 2-9)
🔬Design:Research Article
📍Scope:2020 Verileri
⚙️Variables:Domain Parameters

Özet

Transcatheter aortic valve replacement (TAVR) is a transformative technology that has changed the management of patients with severe, symptomatic aortic stenosis. The use of TAVR in intermediate- to high-risk patients has been validated in several rigorously performed, randomizedclinical trials. Recent studies using newer generation devices have demonstrated the noninferiority of TAVR as compared with surgical aorticvalve replacement in low-risk patients, supporting the increased utilization and expansion of TAVR. The use of TAVR in low-risk patients hasimportant implications and requires a multifaceted approach that includes a highly functional multidisciplinary heart team for careful patientselection; a need to understand and help mitigate certain key complications, such as stroke, paravalvular regurgitation, and conduction disturbances; careful data collection for continual outcome assessment and improvement; and the necessary expertize and procedural volume tomaintain excellent outcomes and ensure optimal clinical care pathways. (Anatol J Cardiol 2020; 23: 2-9)

🔖

Cite This Article

TUZCU, E. M., EDRIS, A. (2020). The implications and requirements of transcatheter aortic valve replacement in low-risk patients. The Anatolian Journal of Cardiology, Cilt: 23 - Sayı: 1, 2–9. https://ajindex.com/articles/365173

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al.; PARTNER Trial Investigators. Transcatheter aortic valve replacement for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363: 1597-607
  2. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al.; PARTNER Trial Investigators. Transcatheter versus surgical aortic valve replacement in high-risk patients. N Engl J Med 2011; 364: 2187-98
  3. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al.; U.S. CoreValve Clinical Investigators. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 2014; 370: 1790-8
  4. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al.; PARTNER 3 Investigators. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2019; 380: 1695-705
  5. Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O'Hair D, et al.; Evolut Low Risk Trial Investigators. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 2019; 380: 1706-15
  6. Kolte D, Vlahakes GJ, Palacios IF, Sakhuja R, Passeri JJ, Inglessis I, et al. Transcatheter versus surgical aortic valve replacement in low-risk patients. J Am Coll Cardiol 2019; 74: 1532-40
  7. Siontis GCM, Overtchouk P, Cahill TJ, Modine T, Prendergast B, Praz F, et al. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. Eur Heart J 2019; 40: 3143-53
  8. Stortecky S, Schoenenberger AW, Moser A, Kalesan B, Jüni P, Carrel T, et al. Evaluation of multidimensional geriatric assessment as a predictor of mortality and cardiovascular events after transcatheter aortic valve implantation. JACC Cardiovasc Interv 2012; 5: 489- 96
  9. Afilalo J, Mottillo S, Eisenberg MJ, Alexander KP, Noiseux N, Perrault LP, et al. Addition of frailty and disability to cardiac surgery risk scores identifies elderly patients at high risk of mortality or major morbidity. Circ Cardiovasc Qual Outcomes 2012; 5: 222-8
  10. Lindman BR, Alexander KP, O'Gara PT, Afilalo J. Futility, benefit, and transcatheter aortic valve replacement. JACC Cardiovasc Interv 2014; 7: 707-16
  11. Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without aortic regurgitation. Circulatio